Table 1.
Direct comparison of the efficacies of ARBs in clinical trials.
| Effects | Efficacies | References |
|---|---|---|
| Reducing left ventricular mass | valsartan > losartan | 39 |
| Increasing nitric oxide production | valsartan>losartan | 40 |
| Lowering plasma plasminogen activator inhibitor type-1 antigen and monocyte chemoattractant protein-1 | candesartan>losartan | 41 |
| Preventing coronary artery contractior | Exp3174>candesartan =valsartan>losartan | 42 |
| Preventing coronary restenosis | valsartan>losartan | 43 |
| Reduction of C-reactive protein | olmesartan>valsartan | 44 |
| Reduction of plasma adiponectin and glucose | telmisartan>candesartan | 45 |
| Inhibition of platelet activation | losartan>valsartan >candesartan | 46 |
| Reduction of interleukin-6 and C-reactive protein | olmesartan>telmisartan | 47 |
| Improvement of glucose and lipid profiles | telmisartan>olmesartan | 48 |